Advanced search
Publication Cover
Clinical Epidemiology Volume 12, 2020 - Issue
Submit an article Journal homepage
156
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Evaluating the Effectiveness of an Additional Risk Minimization Measure to Reduce the Risk of Prescribing Mirabegron to Patients with Severe Uncontrolled Hypertension in Four European Countries

Edith M Heintjes1 PHARMO Institute for Drug Outcomes Research, Utrecht, the NetherlandsCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2617-3845View further author information
ORCID Icon,
Irene D Bezemer1 PHARMO Institute for Drug Outcomes Research, Utrecht, the NetherlandsView further author information
,
Daniel Prieto-Alhambra2 Idiap Jordi Gol Primary Care Research Institute and CIBERFes, Universitat Autonoma de Barcelona and Instituto de Salud Carlos III, Barcelona, Catalonia, Spain;3 Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, England, UKView further author information
,
Elisabeth Smits1 PHARMO Institute for Drug Outcomes Research, Utrecht, the NetherlandsView further author information
,
Helen P Booth4 Clinical Practice Research Datalink (CPRD), London, UKView further author information
,
Daniel Dedman4 Clinical Practice Research Datalink (CPRD), London, UKORCID Iconhttps://orcid.org/0000-0002-3699-5391View further author information
ORCID Icon,
Ying He3 Centre for Statistics in Medicine, NDORMS, University of Oxford, Oxford, England, UKView further author information
,
Fabian Hoti5 Statfinn - EPID Research, Espoo, FinlandView further author information
,
Minna Vehkala5 Statfinn - EPID Research, Espoo, FinlandView further author information
,
Stefan de Vogel6 Astellas Pharma Europe B.V., Leiden, NetherlandsView further author information
,
Noah Jamie Robinson6 Astellas Pharma Europe B.V., Leiden, NetherlandsView further author information
,
Kwame Appenteng7 Astellas Pharma Global Development, Inc., Northbrook, IL, USAView further author information
&
Fernie J A Penning-van Beest1 PHARMO Institute for Drug Outcomes Research, Utrecht, the NetherlandsView further author information
 show all
Pages 423-433 | Published online: 01 May 2020

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Eladio Fernández-Liz, Pere Vivó-Tristante, Antonio Aranzana-Martínez, Maria Estrella Barceló-Colomer, Maria Larrosa-Garcia, José Luís del Val García & Elisabeth Martín-Gracia. (2021) Long-term effectiveness of an intervention to enhance mirabegron use revision and its deprescribing: 36-month follow-up of a quasi-experimental trial in primary care. Current Medical Research and Opinion 37:4, pages 703-710.
Read now

Articles from other publishers (2)

Man Yang, Qiangsheng He, Fang Gao, Krish Nirantharakumar, Tonny Veenith, Xiwen Qin, Amy T. Page, Martin C. S. Wong, Junjie Huang, Zi Chong Kuo, Bin Xia, Changhua Zhang, Yulong He, Wenbo Meng, Jinqiu Yuan & Yihang Pan. (2021) Regular use of proton-pump inhibitors and risk of stroke: a population-based cohort study and meta-analysis of randomized-controlled trials. BMC Medicine 19:1.
Crossref
Veena Hoffman, Jesper Hallas, Marie Linder, Andrea V. Margulis, Brandon T. Suehs, Alejandro Arana, Kelesitse Phiri, Cheryl Enger, Libby Horter, Ingvild Odsbu, Morten Olesen, Susana Perez-Gutthann, Yihua Xu, Nina Sahlertz Kristiansen, Kwame Appenteng, Stefan de Vogel, John D. Seeger, Cheryl Enger, John Seeger, Veena Hoffman, Kelesitse Phiri, Jesper Hallas, Morten Olesen, Nina Sahlertz Kristiansen, Shahram Bahmanyar, Marie Linder, Helle Kieler, Ingvild Odsbu, Alejandro Arana, Lisa McQuay, Andrea Margulis, Susana Perez-Gutthann, Ryan Ziemiecki, Su Bunniran, Brandon Suehs, Claudia Uribe, Yihua Xu, Libby Horter, Kwame Appenteng, Stefan de Vogel, Noah Jamie Robinson, Songlin Xue, Josie Wolfram, Achim Steup, Jena Giese-Pagac, Raymond van Aarle, Neha Sheth, David Burns, Natalie Boone, Mary Beth Blauwet, Milbhor D’Silva, Billy Franks, Willem Jan Atsma, Tim Auton, Edeltraut Garbe, Anders Ekbom, Todd Lee, Noel Weiss, John Rumsfeld, Sara Yuewen Gao, Laura Karslake, Nan Liu, Katherine Reed, Bruce Turnbull, Jing Yang, Nicole Brooks & Kathleen Mortimer. (2021) Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study. Drug Safety 44:8, pages 899-915.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.